Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Neurology
•
Neuro-immunology
Can you use a JAK inhibitor and Mavenclad in a patient with both multiple sclerosis and rheumatoid arthritis?
Related Questions
What is your workup and treatment approach for cranial neuropathies in patients with lupus?
What is your approach to dosing rituximab in patients with multiple sclerosis?
How would you manage a patient with LGI-1 encephalitis with faciobracial dystonic seizures who has not improved with 3 days of intravenous steroids?
How frequently do you recommend ordering labs to monitor for side effects of disease-modifying therapies for multiple sclerosis?
How would you approach the decision to escalate DMT in a patient with relapsing multiple sclerosis who has two to three new T2 lesion but no clinical symptoms?
If a patient develops itching with their first dose of Tysabri despite pre-treatment, does this indicate that further cycles of Tysabri are contraindicated or do you continue Tysabri at the next cycle?
Do you send CSF or serum ACE levels in the workup of neurosarcoidosis?
What is your disease modifying treatment of choice for a patient with relapsing remitting multiple sclerosis with treated, well controlled HIV?
What is your treatment approach to neurological Sjogrens disease with both peripheral neuropathy and transverse myelitis?
Should IVIG dosing in patients with autoimmune disease (i.e., dermatomyositis) who become pregnant continue to be based on actual weight at the time of each infusion, or should it be limited to pre-pregnancy weight?
